Stocks · News reference

SANUWAVE Health Raises Q2 Sales Guidance from $8.500M-$9.500M to $9.600M-$9.800M

Jul 13, 2026, 8:48 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncAug 6, 2026, 9:00 PMNa
Sanuwave Announces Q2 FY2026 Financial Results
Sanuwave Health (NASDAQ: SNWV) reported Q2 2026 revenues of $9.7 million, down 3% year-over-year, with gross margins declining to 76.2% from 78.1%. The company posted an operating loss of $0.3 million versus operating income of $1.4 million in Q2 2025. While Ultramist applicator revenue grew 13%, system sales declined significantly due to CMS reimbursement pressures and a secondary market for used equipment. The company has withdrawn its 2026 guidance pending clarity on Medicare reimbursement developments.
SNWV
SEC EDGARAug 6, 2026, 9:07 PMSEC EDGAR
8-K filing — SANUWAVE Health, Inc. (SNWV)
Filed: 2026-08-06 AccNo: 0001628280-26-054459 Size: 502 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
SNWV
BenzingaAug 6, 2026, 8:42 PMBenzinga Newsdesk
SANUWAVE Health Q2 EPS $(0.08) Down From $(0.04) YoY, Sales $9.739M Down From $10.054M YoY
SANUWAVE Health (NASDAQ:SNWV) reported quarterly losses of $(0.08) per share. This is a 100 percent decrease over losses of $(0.04) per share from the same period last year. The company reported $9.739 million in sales
SNWV
BenzingaJul 17, 2026, 1:42 PMLekha Gupta
What's Going on With SANUWAVE Health Stock on Friday?
NASDAQ:SNWV shares are trading down 0.5% in premarket as SANUWAVE Health beats Q2 revenue expectations, but faces financial constraints and competition.
SNWV